Wellness and healthcare company VLCC today said it has signed a license agreement with the Central Marine Fisheries Research Institute (CMFRI) for exclusive rights to manufacture, market and use Cadalmin ACe extract, found to be effective in combating dyslipidemia1 and obesity. VLCC will have the exclusive rights to manufacture and market Cadalmin Ace nutraceutical, the company said in a statement.
The marine algae-based nutraceutical product, Cadalmin Antihypercholesterolemic (Cadalmin ACe) extract, was developed by CMFRI, a premier Kochi-based marine research establishment of the Indian Council of Agricultural Research. VLCC will be working closely with the CMFRI to source relevant seaweed and manufacture the product as per CMFRI developed technology, the statement added.
“VLCC has been committed to fighting obesity for decades and CadalminACe, with its high level of efficacy and no side effects, will be instrumental in our next stage of fight against obesity. We are confident that it will be well received by consumers in India and across other countries in the world,” VLCC founder Vandana Luthra said.
CMFRI Director A Gopalakrishnan said CadalminAce nutraceutical is a natural remedy for obesity and yslipidemia and does not have any side effects, established by detailed pre-clinical trials.